Eradication of early Pseudomonas infection in cystic fibrosis

Chronic Respiratory Disease

Volumn 6, Issue 2, 2009, Pages 99-107

  Lee, T W R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ciprofloxacin; Intermittent Pseudomonas; Nebulized colomycin; Nebulized tobramycin

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; MOUTHWASH; PLACEBO; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONTROL GROUP; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ERADICATION THERAPY; HUMAN; INFECTION CONTROL; INFECTION RISK; LUNG LAVAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 65149091947     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972309104661     Document Type: Review

References (81)

1. Riordan JRg., Rommens JMg., Kerem Bg., Alon Ng., Rozmahel Rg., Grzelczak Zg.,. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989 ; 245: 1066 - 1073.
2. Morgan WJg., Butler SMg., Johnson CAg., Colin AAg., FitzSimmons SCg., Geller DEg.,. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999 ; 28: 231 - 241.
3. Andersen DHg.,. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938 ; 56: 344 - 399.
4. Cystic Fibrosis Foundation patient registry 2006, Annual Data Report. Bethesda (MD): CF Foundation; 2008.
5. FitzSimmons Sg.,. The changing epidemiology of cystic fibrosis. J Pediatr 1993 ; 122: 1 - 9. (Pubitemid 23010675)
6. Konstan MWg., Morgan WJg., Butler SMg., Pasta DJg., Craib MLg., Silva SJg.,. Risk factors for rate of decline in FEV1 in children and adolescents with cystic fibrosis. J Pediatr 2007 ; 151: 134 - 139.
7. McPhail GLg., Acton JDg., Fenchel MCg., Amin RSg., Seid Mg.,. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and Dornase alfa use. J Pediatr 2008 ; 153: 752 - 757.
8. Kerem Eg., Corey Mg., Gold Rg., Levison Hg.,. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990 ; 116: 714 - 719.
9. Emerson Jg., Rosenfeld Mg., McNamara Sg., Ramsey Bg., Gibson RLg.,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002 ; 34: 91 - 100.
10. Lee TWRg., Brownlee KGg., Conway SPg., Denton Mg., Littlewood JMg.,. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003 ; 2: 29 - 34.
11. Kozlowska WJg., Bush Ag., Wade Ag., Aurora Pg., Carr SBg., Castle RAg.,. Lung function from infancy to the pre-school years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008 ; 178: 42 - 49.
12. Pamukcu Ag., Bush Ag., Buchdahl Rg.,. Effects of Pseudomonas aeruginosa colonization on lung function and anthropomorphic variables in children with cystic fibrosis. Pediatr Pulmonol 1995 ; 19: 10 - 15.
13. Kosorok MRg., Zeng Lg., West SEHg.,. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001 ; 32: 277 - 287.
14. Henry RLg., Mellis CMg., Petrovic Lg.,. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992 ; 12: 158 - 161.
15. Courtney JMg., Bradley Jg., McCaughan Jg., OgConnor TMg., Shortt Cg., Bredin CPg.,. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007 ; 42: 525 - 532.
16. Burns JLg., Gibson RLg., McNamara Sg., Yim Dg., Emerson Jg., Rosenfeld Mg.,. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001 ; 183: 444 - 452.
17. Hansen CRg., Pressler Tg., Hiby Ng.,. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonisation in CF patients: 15 years experience. J Cyst Fibros 2008 ; 7: 523 - 530.
18. Frederiksen Bg., Koch Cg., Hoiby Ng.,. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999 ; 28: 159 - 166.
19. Proesmans Mg., Balinska-Miskiewicz Wg., Dupont Lg., Bossuyt Xg., Verhaegen Jg., Hiby Ng.,. Evaluating the gLeeds criteriag for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 2006 ; 27: 937 - 943.
20. Wood DM; g.,Smyth AR; g.,. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; (1): Art. No.: CD004197. DOI: 10.1002/14651858.CD004197.pub2.
21. Treggiari MMg., Rosenfeld Mg., Retsch-Bogart Gg., Gibson Rg., Ramsey Bg.,. Approach to eradication of initial Pseudomonas aeruginosa infection in people with cystic fibrosis. Pediatr Pulmonol 2007 ; 42: 751 - 756.
22. Mitcherlich Eg., Marth EHg.,. Microbial Survival in the Environment. Berlin: Springer ; 1984.
23. Moore JEg., Heaney Ng., Millar BCg., Crowe Mg., Elborn JSg.,. Incidence of Pseudomonas aeruginosa in recreational and hydrotherapy pools. Commun Dis Public Health 2002 ; 5: 23 - 26.
24. Schelstraete Pg., Van daele Sg., De Boeck Kg., Proesmans Mg., Lebecque Pg., Leclercq-Foucart Jg.,. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients. Eur Respir J 2008 ; 31: 822 - 829.
25. Jensen ETg., Giwercman Bg., Ojeniyi Bg., Bangsbord JMg., Hansen Ag., Koch Cg.,. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect 1997 ; 36: 117 - 122.
26. Barben Jg., Schmid Jg.,. Dental units as infection sources of Pseudomonas aeruginosa. Eur Respir J 2008 ; 32: 1122 - 1123.
27. Doring Gg., Jansen Sg., Noll Hg., Grupp Hg., Frank Fg., Botzenhart Kg.,. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996 ; 21: 90 - 100.
28. Doring Gg., Ulrich Mg., Muller Wg.,. Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl Hyg Umweltmed 1991 ; 191: 494 - 505.
29. Jones AMg., Govan JRg., Doherty CJg., Dodd MEg., Isalska BJg., Stanbridge TNg.,. Spread of a multi-resistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001 ; 358: 557 - 558.
30. McCallum SJg., Corkill JEg., Gallagher MJg., Ledson MJg., Hart CAg., Walshaw MJg.,. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001 ; 358: 558 - 560.
31. Denton Mg., Kerr KGg., Mooney Lg., Keer Vg., Rajgopal Ag., Brownlee Kg.,. Transmission of a colistin-resistant Pseudomonas aeruginosa between patients attending a paediatric cystic fibrosis centre. Pediatr Pulmonol 2002 ; 34: 257 - 261.
32. Armstrong DSg., Bell SCg., Robinson Mg., Bye Pg., Rose Bg., Harbour Cg.,. Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol 2003 ; 41: 2266 - 2267.
33. Brimicombe RWg., Dijkshoorn Lg., van der Reijden TJg., Kardoes Ig., Pitt TLg., van den Broek PJg.,. Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in the Netherlands. J Cyst Fibros 2008 ; 7: 30 - 36.
34. Jones AMg., Govan JRg., Doherty CJg., Dodd MEg., Isalska BJg., Stanbridge TNg.,. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross-infection outbreak. Thorax 2003 ; 58: 525 - 527. (Pubitemid 36714016)
35. Panagea Sg., Winstanley Cg., Walshaw MJg., Ledson MJg., Hart CAg.,. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect 2005 ; 59: 102 - 107. (Pubitemid 40058035)
36. Clifton IJg., Fletcher LAg., Beggs CBg., Denton Mg., Peckham DGg.,. A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. BMC Microbiol 2008 ; 8: 105.
37. Frederiksen Bg., Lanng Sg., Koch Cg., Hoiby Ng.,. Improved survival in the Danish-centre treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996 ; 21: 153 - 158.
38. Lee TWg., Brownlee KGg., Denton Mg., Littlewood JMg., Conway SPg.,. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis centre. Pediatr Pulmonol 2004 ; 37: 104 - 110.
39. Festini Fg., Buzzetti Rg., Bassi Cg., Braggion Cg., Salvatore Dg., Taccetti Gg.,. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review. J Hosp Infect 2006 ; 64: 1 - 6. (Pubitemid 44161372)
40. Douglas TAg., Brennan Sg., Gard Sg., Berry Lg., Gangell Cg., Stick SMg.,. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2008 ; epub ahead of print.
41. Johansen HKg., Gtzsche PCg.,. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008 ; 4: CD001399.
42. Levy Hg., Kalish LAg., Cannon CLg., Garca KCg., Gerard Cg., Goldmann Dg.,. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol 2008 ; 43: 463 - 471.
43. Rosenfeld Mg., Gibson RLg., McNamara Sg., Emerson Jg., Burns JLg., Castile Rg.,. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001 ; 32: 356 - 366.
44. Dakin CJg., Numa AHg., Wang Hg., Morton JRg., Vertzyas CCg., Henry RLg.,. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002 ; 165: 904 - 910.
45. Rosenfeld Mg., Emerson Jg., Accurso Fg., Armstrong Dg., Castile Rg., Grimwood Kg.,. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999 ; 28: 321 - 328.
46. De Boeck Kg., Alifier Mg., Vandeputte Sg.,. Sputum induction in young cystic fibrosis patients. Eur Respir J 2000 ; 16: 91 - 94.
47. Ho SAg., Ball Rg., Morrison LJg., Brownlee KGg., Conway SPg.,. Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004 ; 38: 82 - 87. (Pubitemid 38823762)
48. Ratjen Fg., Walter Hg., Haug Mg., Meisner Cg., Grasemann Hg., Dring Gg.,. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007 ; 42: 249 - 255.
49. Brett MMg., Ghoneim ATMg., Littlewood JMg.,. Prediction and diagnosis of early P. aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol 1988 ; 26: 1565 - 1570.
50. West SEg., Zeng Lg., Lee BLg., Kosorok MRg., Laxova Ag., Rock MJg.,. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002 ; 287: 2958 - 2967.
51. Littlewood JMg., Miller MGg., Ghoneim ATg., Ramsden CHg.,. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985 ; 1: 865.
52. Doring Gg., Hoiby Ng.,. ; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004 ; 3: 67 - 91.
53. Valerius NHg., Koch Cg., Hiby Ng.,. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991 ; 338: 725 - 726.
54. Wiesemann HGg., Steinkamp Gg., Ratjen Fg., Bauernfeind Ag., Przyklenk Bg., Dring Gg.,. Placebo-controlled, double-blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998 ; 25: 88 - 92.
55. Gibson RLg., Emerson Jg., McNamara Sg., Burns JLg., Rosenfeld Mg., Yunker Ag.,. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 ; 167: 841 - 849.
56. Munck Ag., Bonacorsi Sg., Mariani-Kurkdjian Pg., Lebourgeois Mg., Grardin Mg., Brahimi Ng.,. Genotypic characterisation of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation. Pediatr Pulmonol 2001 ; 32: 288 - 292.
57. Taccetti Gg., Campana Sg., Festini Fg., Mascherini Mg., Dring Gg.,. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005 ; 26: 458 - 461.
58. Ratjen Fg., Stenglein Sg., Munck Ag.,. Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: The ELITE study. J Cyst Fibros 2008 ; 7 (Suppl. 2): S26.
59. http://www.clinicaltrials.gov/ct/gui/show
60. Wainwright Cg., Carlin Jg., Cooper Pg.,. Australasian cystic fibrosis BAL study interim analysis. Pediatr Pulmonol 2006 ; (Suppl. 29): 317.
61. Denton Mg., Brownlee KGg., Conway Sg., Lee Tg., Peckham Dg.,. Early eradication therapy for Pseudomonas aeruginosa: impact of prior clinical status and choice of antibiotic regimen on eradication rates. J Cyst Fibros 2006 ; 5 (Suppl. 1): S22.
62. Modi ACg., Lim CSg., Yu Ng., Geller Dg., Wagner MHg., Quittner ALg.,. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006 ; 5: 177 - 185.
63. Ho SAg., Lee TWRg., Denton Mg., Conway SPg., Brownlee KGg.,. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros 2009 ; 8: 43 - 46.
64. Becker JWg., Burke Wg., McDonald Gg., Greenberger PAg., Henderson WRg., Aitken MLg.,. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996 ; 109: 1536 - 1540.
65. Shoseyov Dg., Brownlee KGg., Conway SPg., Kerem Eg.,. Aspergillus bronchitis in cystic fibrosis. Chest 2006 ; 130: 222 - 226. (Pubitemid 44116864)
66. Byrne NMg., Keavey PMg., Perry JDg., Gould FKg., Spencer DAg.,. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch Dis Child 2003 ; 88: 715 - 718.
67. Modi ACg., Quittner ALg.,. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way ? J Pediatr Psychol 2006 ; 31: 846 - 858.
68. Ferguson Jg., McEwen Jg., Al-Ajmi Hg., Purkins Lg., Colman PJg., Willavize SAg.,. A comparison of the photosensitizing potential of trovafloxin with that of the other quinolones in healthy subjects. J Antimicrob Chemother 2000 ; 45: 503 - 509.
69. Dodd MEg., Abbott Jg., Maddison Jg., Moorcroft AJg., Webb AKg.,. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997 ; 52: 656 - 658.
70. Cunningham Sg., Prasad Ag., Collyer Lg., Carr Sg., Lynn IBg., Wallis Cg.,. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001 ; 84: 432 - 433.
71. Alothman GAg., Alsaadi MMg., Ho BLg., Ho SLg., Dupuis Ag., Corey Mg.,. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002 ; 122: 930 - 934.
72. Kishida Mg., Suzuki Ig., Kabayama Hg., Koshibu Tg., Izawa Mg., Takeshita Yg.,. Mouthpiece versus facemask for delivery of nebulised salbutamol in exacerbated childhood asthma. J Asthma 2002 ; 39: 337 - 339. (Pubitemid 34671108)
73. Hutchinson GRg., Parker Sg., Pryor JAg., Duncan-Skingle Fg., Hoffman PNg., Hodson MEg.,. Home-use nebulisers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996 ; 34: 584 - 587.
74. Denton Mg., Rajgopal Ag., Mooney Lg., Qureshi Ag., Kerr KGg., Keer Vg.,. Stenotrophomonas maltophilia contamination of nebulisers used to deliver aerosolised therapy to inpatients with cystic fibrosis. J Hosp Infect 2003 ; 55: 180 - 183. (Pubitemid 37554907)
75. Bakuridze Lg., Andrieu Vg., Dupont Cg., Dubus JCg.,. Does repeated disinfection of the e-Flow rapid nebuliser affect in vitro performance ? J Cyst Fibros 2007 ; 6: 309 - 310.
76. Nilsson Eg., Larsson Ag., Olesen HVg., Wejker PEg., Kollberg Hg.,. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 2008 ; 43: 892 - 899.
77. Ullrich Gg., Wiedau Sg., Schulz Wg., Steinkamp Gg.,. Parental knowledge and behaviour to prevent environmental P. aeruginosa acquisition in their children with CF. J Cyst Fibros 2008: 231 - 237.
78. Goldbeck Lg., Zerrer Sg., Schmitz TGg.,. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J Cyst Fibros 2007 ; 6: 171 - 178.
79. Conway SPg., Pond MNg., Hamnett Tg., Watson Ag.,. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996 ; 51: 29 - 33.
80. Latchford Gg., Duff Ag., Quinn Jg., Conway Sg., Conner Mg.,. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2008 ; epub ahead of print.
81. Duff AJAg., Latchford Gg., Moore MWg., Riekert KAg.,. Motivational interviewing skills for changing health behaviours. Pediatr Pulmonol 2006 ; (Suppl. 29): 10.